Therapeutic application of tumour cell‐derived extracellular vesicles for drug‐resistant cancer therapy via interleukin 6/signal transducer and activator of transcription 3 signalling pathway

Numerous studies have demonstrated that targeting this axis is beneficial for anti-cancer treatment. [...]IL-6/JAK/STAT3 pathway has been shown to be the main effector to mediate the downstream signals activated by EGFR and thereby exert a critical role in the Erlotinib resistance of NSCLC. First by...

Full description

Saved in:
Bibliographic Details
Published inClinical and translational discovery Vol. 2; no. 3
Main Authors Zhou, Manqian, Wang, Hui, Li, Zongjin
Format Journal Article
LanguageEnglish
Published Birtinya John Wiley & Sons, Inc 01.09.2022
Wiley
Subjects
Cancer therapies
Conflicts of interest
Cytokines
Extracellular vesicles
Kinases
Lung cancer
Stem cells
Online AccessGet full text

Cover

More Information
Summary:Numerous studies have demonstrated that targeting this axis is beneficial for anti-cancer treatment. [...]IL-6/JAK/STAT3 pathway has been shown to be the main effector to mediate the downstream signals activated by EGFR and thereby exert a critical role in the Erlotinib resistance of NSCLC. First by bioinformatics analysis, they identified IL-6 to be a core correlation factor and that APE1/IL-6/STAT3 might be the key signalling in modulation with Erlotinib resistance of NSCLC. [...]EVs physiologically encapsulate and convey a broad range of biomolecular components including metabolites, proteins and nucleic acids to intended cells for an exchange of information and substances.
ISSN:2768-0622
2768-0622
DOI:10.1002/ctd2.105